| Product Code: ETC4720306 | Publication Date: Nov 2023 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
In 2024, Belgium continued to rely on imports of human insulin, with key exporting countries being the USA, Austria, Netherlands, Hungary, and the UK. Despite high concentration with a high Herfindahl-Hirschman Index (HHI), the market saw impressive growth with a Compound Annual Growth Rate (CAGR) of 39.8% from 2020 to 2024. However, there was a notable decline in growth rate from 2023 to 2024 at -59.2%, indicating potential shifts in market dynamics or external factors impacting the import landscape.

The human insulin market in Belgium is driven by the rising prevalence of diabetes and the demand for effective diabetes management solutions. The market includes various insulin formulations, such as rapid-acting, long-acting, and premixed insulins. Advances in biotechnology and the introduction of biosimilar insulins contribute to market growth. Additionally, increasing awareness about diabetes care and advancements in insulin delivery devices play a significant role in shaping the market landscape.
The human insulin market in Belgium is driven by the increasing prevalence of diabetes and the growing demand for effective management of blood glucose levels. Advances in insulin delivery systems, including the development of long-acting and rapid-acting insulin formulations, contribute to market growth. The rise in healthcare spending, awareness programs, and improved diagnosis rates of diabetes further support the demand for human insulin. Additionally, the expansion of diabetes care infrastructure and the introduction of innovative insulin therapies drive the market.
The Human Insulin market in Belgium faces challenges such as high production costs and pricing pressures from both regulatory bodies and consumers. There are stringent regulatory requirements for the approval and quality control of insulin products. Additionally, the market must address the growing competition from biosimilars and other alternative diabetes treatments. Managing supply chain complexities and ensuring consistent product availability are also significant concerns.
The Belgian government regulates the human insulin market through stringent health and safety standards. The European Medicines Agency (EMA) oversees the approval and monitoring of insulin products, ensuring their efficacy and safety for diabetic patients. Belgium adheres to these regulations, which include rigorous testing and quality control processes to ensure that insulin products meet high standards of safety and effectiveness.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Belgium Human Insulin Market Overview |
3.1 Belgium Country Macro Economic Indicators |
3.2 Belgium Human Insulin Market Revenues & Volume, 2021 & 2031F |
3.3 Belgium Human Insulin Market - Industry Life Cycle |
3.4 Belgium Human Insulin Market - Porter's Five Forces |
3.5 Belgium Human Insulin Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Belgium Human Insulin Market Revenues & Volume Share, By Diabetes Type, 2021 & 2031F |
3.7 Belgium Human Insulin Market Revenues & Volume Share, By Delivery Devices, 2021 & 2031F |
3.8 Belgium Human Insulin Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 Belgium Human Insulin Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in Belgium |
4.2.2 Growing geriatric population in the country |
4.2.3 Technological advancements in insulin delivery devices |
4.2.4 Favorable government initiatives for diabetes management |
4.2.5 Rising awareness about diabetes and its complications |
4.3 Market Restraints |
4.3.1 High cost associated with insulin therapy |
4.3.2 Stringent regulatory requirements for insulin products |
4.3.3 Competition from alternative therapies like oral antidiabetic drugs |
4.3.4 Limited access to healthcare facilities in rural areas |
4.3.5 Potential risks of hypoglycemia and weight gain associated with insulin use |
5 Belgium Human Insulin Market Trends |
6 Belgium Human Insulin Market Segmentations |
6.1 Belgium Human Insulin Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Belgium Human Insulin Market Revenues & Volume, By Analogue Insulin, 2021-2031F |
6.1.3 Belgium Human Insulin Market Revenues & Volume, By Traditional Human Insulin, 2021-2031F |
6.2 Belgium Human Insulin Market, By Diabetes Type |
6.2.1 Overview and Analysis |
6.2.2 Belgium Human Insulin Market Revenues & Volume, By Type 1 Diabetes, 2021-2031F |
6.2.3 Belgium Human Insulin Market Revenues & Volume, By Type 2 Diabetes, 2021-2031F |
6.2.4 Belgium Human Insulin Market Revenues & Volume, By Gestational Diabetes, 2021-2031F |
6.2.5 Belgium Human Insulin Market Revenues & Volume, By Prediabetes, 2021-2031F |
6.3 Belgium Human Insulin Market, By Delivery Devices |
6.3.1 Overview and Analysis |
6.3.2 Belgium Human Insulin Market Revenues & Volume, By Syringes, 2021-2031F |
6.3.3 Belgium Human Insulin Market Revenues & Volume, By Pens, 2021-2031F |
6.3.4 Belgium Human Insulin Market Revenues & Volume, By Pumps, 2021-2031F |
6.3.5 Belgium Human Insulin Market Revenues & Volume, By Others, 2021-2031F |
6.4 Belgium Human Insulin Market, By End-users |
6.4.1 Overview and Analysis |
6.4.2 Belgium Human Insulin Market Revenues & Volume, By Home Healthcare, 2021-2031F |
6.4.3 Belgium Human Insulin Market Revenues & Volume, By Hospitals, 2021-2031F |
6.4.4 Belgium Human Insulin Market Revenues & Volume, By Over The Counter (OTC), 2021-2031F |
6.4.5 Belgium Human Insulin Market Revenues & Volume, By Clinics, 2021-2031F |
6.4.6 Belgium Human Insulin Market Revenues & Volume, By Others, 2021-2031F |
7 Belgium Human Insulin Market Import-Export Trade Statistics |
7.1 Belgium Human Insulin Market Export to Major Countries |
7.2 Belgium Human Insulin Market Imports from Major Countries |
8 Belgium Human Insulin Market Key Performance Indicators |
8.1 Average HbA1c levels among diabetic patients in Belgium |
8.2 Adoption rate of advanced insulin delivery systems in the market |
8.3 Number of diabetes education programs and campaigns conducted annually |
8.4 Percentage of diabetic patients achieving target glucose control levels |
8.5 Rate of hospitalizations due to diabetes-related complications |
9 Belgium Human Insulin Market - Opportunity Assessment |
9.1 Belgium Human Insulin Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Belgium Human Insulin Market Opportunity Assessment, By Diabetes Type, 2021 & 2031F |
9.3 Belgium Human Insulin Market Opportunity Assessment, By Delivery Devices, 2021 & 2031F |
9.4 Belgium Human Insulin Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 Belgium Human Insulin Market - Competitive Landscape |
10.1 Belgium Human Insulin Market Revenue Share, By Companies, 2024 |
10.2 Belgium Human Insulin Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |